10 Stocks I'm Looking at Right Now
April Watchlist Update
To read our full disclaimer, click here.
I like keeping my watchlist concise.
Only the names I’m really interested in following.
These are the names I’ll do write-ups on in the coming months. Obviously, some may drop off and some may become part of the portfolio. But here’s a look at the 10 items currently on it.
The 10 Stocks
A 30-year-old subsea offshore specialist quietly growing 40% in a contracting industry - new CEO has flipped losses into profits without needing oil to cooperate.
A boring cash-generating piece of internet plumbing being deliberately rebuilt as an acquisition vehicle by a Canadian capital allocator with a documented 200-bagger to his name.
A two-sided network business where every unit sold becomes a permanent royalty annuity. Royalties up 31%, EBITDA up 112%, fresh 10% buyback, and insiders accumulating in the open market.
A vertically integrated avionics turnaround whose systems sit inside aircraft cockpits for 20–30 years. Q1 was a monster, the stock has already run, and now I’m waiting for the entry.
An orphan-drug roll-up that buys rights nobody else will commercialise. The biggest binary catalyst just resolved in shareholders’ favour - with a label far better than I’d modelled.
A capital-light operator riding a structural healthcare workforce shortage of ~1.9M jobs a year. Fourteen straight quarters of double-digit revenue growth and basically no analyst coverage.
An aspiring ingredient brand trying to become the next Gore-Tex. Patented material already embedded in Arc’teryx, North Face, and Black Diamond - and the capacity is about to expand 10x.
A famous compounder cut down 36% on AI fears that probably don’t apply to its actual customer base. Operating income +29%, free cash flow +153%, and the playbook is one of the most respected in capital allocation.
The European cousin of #8 - same playbook, same sell-off, same misunderstanding. Plus a lumpy non-cash accounting charge that scared investors out of a perfectly healthy operating business.
A best-in-class insurance broker compounder hit by a P&C pricing cycle. Stock down ~45%, organic growth flat, but eight acquisitions in Q1 and a $1.15B buyback authorisation say management thinks the cycle is the whole problem.